Description
The novel TH17-associated cytokine IL-26 mediates BBB breakdown and neuroinflammation
Amendment chain · 1 entry
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header.
- #02014-10-01$724,680
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2014-10-01(start date) | $724,680 | — | The novel TH17-associated cytokine IL-26 mediates BBB breakdown and neuroinflammation |
Related records · 3
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (exact legal name match; no business number on file)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 236-2014-2015-Q4-00053 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $1,400,000 | FY2016 |
| 236-2014-2015-Q3-00085 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $112,500 | FY2015 |
| 236-2013-2014-Q2-00442 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $736,121 | FY2014 |
Cite as: Glassbox record view · Federal grants & contributions · 236-2014-2015-Q2-00457 · retrieved 2026-11-14.